Biomay receives FDA approval for the production of Cas9 nuclease at its headquarters

Biomay AG [Newsroom]Vienna (ots) - The company announces that the US Food and Drug Administration (FDA) has approved the production, testing and release of recombinant Cas9 nuclease at its headquarters. Cas9 is an essential part of the company's ... Continue reading here...Original content of: Biomay AG, news transmitted by currently

Vienna (ots) – The Company announces that the US Food and Drug Administration (FDA) has approved the production, testing and release of recombinant Cas9 nuclease at its headquarters. Cas9 is an essential component of CRISPR-based gene editing therapies, including CASGEVY® (exagamglogen autotemcel), developed and launched by Vertex Pharmaceuticals. Biomay's recent success relates to an inspection by the FDA's Center for Biologicals Evaluation and…